Clinical Trial Update: Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Bryostatin 1 in combination with Paclitaxel for stage IIIB, stage IV, or recurrent non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bryostatin-1 (bryostatin-1)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: University of Chicago | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED